Zackery A. Hicks
Known title: DirectorCIK: 0001757126
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Kimberly-Clark Guidance Reiterated as Sales Slip, Bond Sale Planned. Kimberly‑Clark confirmed its full‑year guidance even though recent sales were weaker than expected, which analysts at UBS said could help keep the stock stable. The company is also preparing a bond issuance to fund its planned purchase of a Tylenol‑making business. Shares have fallen about 13% and are trading near a long‑standing support level, while the dividend growth streak faces pressure. The mixed performance of consumer stocks and the stock’s inclusion in dividend‑focused lists add further context.
Transaction History
| SIG | ▲ Buy | Grant | 9 | $0 | 8/21/2026 | View on chart |
| SIG | ▲ Buy | Grant | 2,018 | $0 | 6/26/2026 | View on chart |
| SIG | ▲ Buy | Grant | 9 | $0 | 5/22/2026 | View on chart |
| SIG | ▲ Buy | Grant | 7 | $0 | 2/20/2026 | View on chart |
| SIG | ▲ Buy | Grant | 7 | $0 | 11/21/2025 | View on chart |
| SIG | ▲ Buy | Grant | 8 | $0 | 8/22/2025 | View on chart |
| KMB | ▼ Sell | Open Market | 15,038 | $2.0M | 8/4/2025 | View on chart |
| KMB | ▲ Buy | Grant | 38,098 | $0 | 7/29/2025 | View on chart |
| KMB | ▲ Buy | Option Exercise | 5,361 | $0 | 7/29/2025 | View on chart |
| KMB | ▼ Sell | Tax Withholding | 2,659 | $340K | 7/29/2025 | View on chart |
| KMB | ▼ Sell | Tax Withholding | 18,889 | $2.4M | 7/29/2025 | View on chart |
| SIG | ▲ Buy | Grant | 2,014 | $0 | 7/1/2025 | View on chart |
| KMB | ▲ Buy | Option Exercise | 2,733 | $0 | 5/1/2025 | View on chart |
| KMB | ▼ Sell | Tax Withholding | 1,356 | $176K | 5/1/2025 | View on chart |
| KMB | ▲ Buy | Option Exercise | 2,696 | $0 | 4/26/2025 | View on chart |
| KMB | ▼ Sell | Tax Withholding | 1,337 | $176K | 4/26/2025 | View on chart |
| KMB | ▲ Buy | Option Exercise | 5,171 | $0 | 7/29/2024 | View on chart |
| KMB | ▼ Sell | Tax Withholding | 2,036 | $287K | 7/29/2024 | View on chart |
| SIG | ▲ Buy | Grant | 1,641 | $0 | 6/28/2024 | View on chart |
| KMB | ▲ Buy | Option Exercise | 2,602 | $0 | 4/26/2024 | View on chart |
| KMB | ▼ Sell | Tax Withholding | 1,025 | $139K | 4/26/2024 | View on chart |
| KMB | ▼ Sell | Open Market | 3,020 | $361K | 10/25/2023 | View on chart |
| SIG | ▼ Sell | Open Market | 10,000 | $710K | 10/3/2023 | View on chart |
| KMB | ▲ Buy | Option Exercise | 4,980 | $0 | 7/29/2023 | View on chart |
| KMB | ▼ Sell | Tax Withholding | 1,960 | $256K | 7/29/2023 | View on chart |
| SIG | ▲ Buy | Grant | 2,467 | $0 | 6/16/2023 | View on chart |
| SIG | ▲ Buy | Grant | 2,667 | $0 | 6/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Signet Shares Rise 8.4% Post-Earnings; Blue Nile Partners with Royal Asscher
Signet shares have climbed 8.4% since the last earnings report, moving against a broader market dip. The company also announced that its Blue Nile brand is partnering with Royal Asscher, a move that may strengthen its product lineup. With an average analyst target of $125.90, the stock remains well below that level, sitting near its 52-week high of $110.20.
Signet Shares Rise 8.4% Post-Earnings; Blue Nile Partners with Royal Asscher. Signet shares have climbed 8.4% since the last earnings report, moving against a broader market dip. The company also announced that its Blue Nile brand is partnering with Royal Asscher, a move that may strengthen its product lineup. With an average analyst target of $125.90, the stock remains well below that level, sitting near its 52-week high of $110.20.